Open Accessibility Menu

Monoclonal Antibody Treatment

Monoclonal antibody treatment is a one-time emergency use authorized treatment for eligible patients with mild or moderate COVID-19 symptoms. When administered within 10 days of their first symptoms appearing, this one-time treatment can significantly reduce a patient’s risk of hospitalization, minimize the severity of symptoms and help them recover more quickly. This therapy is also indicated in some high-risk patients for post-exposure and pre-exposure prophylaxis.

OU Health offers monoclonal antibody treatment for individuals over the age of 16 at OU Health Edmond Medical Center from 8 am to 5 pm, Monday through Friday. Individuals under the age of 16 receive monoclonal antibody treatment at Oklahoma Children's Hospital.

Inclusion Criteria

Patients must meet the following requirements:

  • Positive COVID-19 test with mild or moderate symptoms, or recently exposed to COVID-19
  • Symptoms for less than 10 days
  • Do not need supplemental oxygen for breathing due to COVID-19
  • High-risk for progression to severe COVID-19 as defined below.

Patients at higher-risk of severe COVID-19 and would benefit from MAB treatment include:

  • 65 years or older
  • Obese or overweight (i.e., BMI of 25 or greater)
  • Pregnant
  • Diabetes
  • Sickle cell disease.
  • Chronic kidney disease.
  • Immunosuppressive disease or immunosuppressive treatment
  • Cardiovascular disease.
  • Chronic lung disease, such as COPD/asthma, pulmonary hypertension or cystic fibrosis)
  • Neurodevelopment disorder, such as cerebral palsy)
  • Medical-related technological dependence. This might be something like a tracheostomy, gastrostomy or positive pressure ventilation.

There may be other medical conditions or factors that may place your patient at a high risk for progressing to severe COVID-19 symptoms. If you have any questions, please call OU Health Edmond Medical Center — Pharmacy at (405) 359-5333.

Exclusion Criteria

  • Currently hospitalized due to COVID-19
  • Need oxygen therapy due to COVID-19
  • Between the ages of 12-17 and weigh less than 88 pounds

How to Refer a Patient to OU Health’s MAB Treatment Center

  • Complete this online referral form and fax to (405) 359-5240. Currently, referrals are only accepted from OU Health Physicians.
  • Eligible patients typically are contacted by Central Scheduling to receive treatment next day.
  • If you would like to refer a patient under the age of 16 for a pediatric monoclonal antibody treatment, please email

If your patient has any questions on what to expect, please direct them to these frequently asked questions.

Treatment Prioritization

When resources are insufficient to provide antibodies to all qualifying patients, OU Health will follow the recommendations of the NIH to provide monoclonal antibodies to those at greatest risk of severe illness and death from COVID-19.

Types of Monoclonal Antibody Treatments

  • Casirivimab & Imdevimab, Manufacturer – Regeneron
  • Casirivimab and Imdevimab EUA Fact Sheet for Providers
  • GSK Sotrovimab, Manufacturer – GlaxoSmithKline
  • GSK Sotrovimab EUA Fact Sheet for Providers
  • Eli Lilly Bamlanivimab & Etesevimab
  • Bamlanivimab and Etesevimab EUA Fact Sheet For Providers

While reactions to MAB treatments are rare, medications do come with the risk of allergic reaction. The staff and pharmacists in our infusion center are trained to address any reaction, including: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.